A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature.


Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
02 2020
Historique:
received: 27 11 2019
accepted: 05 01 2020
pubmed: 16 1 2020
medline: 22 6 2021
entrez: 16 1 2020
Statut: ppublish

Résumé

Pseudohypoparathyroidism (PHP), characterized by multihormone resistance and Albright's hereditary osteodystrophy (AHO), is caused by GNAS mutations. Whole or partial gene deletions are rare. All disorders due to inactivating mutations of the GNAS gene are now classified as "inactivating PTH/PTHrP signaling disorder type 2" (iPPSD2). This study reports a family harboring a large GNAS gene deletion in order to improve the knowledge of genotype-phenotype correlation of this disease. An 18-year-old man with severe diffuse soft ossifications and multihormone resistance underwent to clinical, biochemical, radiological, and genetic studies. A review of the literature of other cases of iPPSD2 due to GNAS large deletions was performed focusing on clinical and biochemical features. The proband presented signs of hypocalcemia and marked AHO features. Laboratory tests revealed hypocalcemia, high levels of serum phosphate, PTH, TSH, and calcitonin despite therapy with calcium carbonate, calcitriol, and levothyroxine. Diffuse soft tissue ossifications and brain calcifications were shown by radiological exams. Family history was remarkable for hypocalcemia, neurocognitive impairment, and cerebral calcifications in his brother and AHO features in the maternal grandfather. The proband's mother showed short stature, whereas physical examination of the father was unremarkable. Genetic analysis of the GNAS gene revealed an unreported large deletion encompassing exons 1-7 in the proband, brother, and mother. By reviewing the literature, only six other cases were described. We report a kindred harboring a large GNAS deletion. A genotype-phenotype correlation was observed in term of severity of tissue ossifications in the siblings but not in the mother.

Identifiants

pubmed: 31939093
doi: 10.1007/s12020-020-02195-7
pii: 10.1007/s12020-020-02195-7
doi:

Substances chimiques

Chromogranins 0
Parathyroid Hormone-Related Protein 0
GNAS protein, human EC 3.6.1.-
GTP-Binding Protein alpha Subunits, Gs EC 3.6.5.1

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

466-472

Références

J Clin Endocrinol Metab. 2004 Dec;89(12):6316-9
pubmed: 15579796
Horm Metab Res. 2012 Sep;44(10):732-40
pubmed: 22730013
J Clin Endocrinol Metab. 2010 Feb;95(2):765-71
pubmed: 20008020
Am J Med Genet A. 2012 Jan;158A(1):261-4
pubmed: 22140064
Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):941-954
pubmed: 30665554
Proc Natl Acad Sci U S A. 1990 Nov;87(21):8287-90
pubmed: 2122458
J Clin Endocrinol Metab. 2015 Apr;100(4):E681-7
pubmed: 25594858
Eur J Endocrinol. 2016 Dec;175(6):P1-P17
pubmed: 27401862
Exp Clin Endocrinol Diabetes. 2010 Feb;118(2):127-32
pubmed: 19658058
Mol Genet Genomic Med. 2015 Mar;3(2):111-20
pubmed: 25802881
J R Soc Med. 1995 Aug;88(8):483
pubmed: 7562839
J Endocrinol. 2008 Feb;196(2):193-214
pubmed: 18252944
Bone. 2017 Oct;103:281-286
pubmed: 28711660
Front Horm Res. 2019;51:147-159
pubmed: 30641531
Hum Mutat. 2013 Mar;34(3):411-6
pubmed: 23281139
J Bone Miner Res. 2016 Apr;31(4):796-805
pubmed: 26479409
Hum Mutat. 2015 Jan;36(1):11-9
pubmed: 25219572
Exp Clin Endocrinol Diabetes. 2013 Oct;121(9):539-45
pubmed: 24127307

Auteurs

Alessandro Brancatella (A)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Giovanna Mantovani (G)

Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Endocrinology Unit, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Francesca M Elli (FM)

Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Endocrinology Unit, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Simona Borsari (S)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Claudio Marcocci (C)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Filomena Cetani (F)

Endocrine Unit 2, University Hospital of Pisa, Pisa, Italy. cetani@endoc.med.unipi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH